Intec Pharma (NASDAQ:NTEC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

NTEC has been the topic of a number of other research reports. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research note on Friday, October 13th. ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Maxim Group set a $8.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a report on Friday, November 17th. Finally, CIBC restated an “outperform” rating and set a $15.00 target price (up from $10.00) on shares of Intec Pharma in a report on Thursday, September 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $10.70.

Intec Pharma (NASDAQ:NTEC) traded up $0.90 during midday trading on Wednesday, hitting $6.05. 272,400 shares of the company were exchanged, compared to its average volume of 347,400. Intec Pharma has a fifty-two week low of $4.20 and a fifty-two week high of $9.80. The firm has a market capitalization of $134.26 and a price-to-earnings ratio of -5.17.

A number of institutional investors have recently bought and sold shares of the stock. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Intec Pharma by 5.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after purchasing an additional 25,000 shares during the period. Caxton Corp purchased a new stake in Intec Pharma in the 3rd quarter worth approximately $681,000. Pura Vida Investments LLC purchased a new stake in Intec Pharma in the 3rd quarter worth approximately $895,000. Finally, Sectoral Asset Management Inc purchased a new stake in Intec Pharma in the 3rd quarter worth approximately $3,177,000. 40.16% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/03/intec-pharma-ntec-lowered-to-hold-at-zacks-investment-research.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.